Instrument Inactif

Autres langues NuGenerex Immuno-Oncology, Inc.

Actions

NUGX

US67053X1028

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

NUGENEREX IMMUNO-ONCOLOGY, INC. : Changes in Control or Registrant, Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)	10/04/23
NUGENEREX IMMUNO-ONCOLOGY, INC. : Other Events (form 8-K)	23/07/21
NUGENEREX IMMUNO ONCOLOGY : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	14/06/21
Nugenerex Immuno-Oncology, Inc. Reports Earnings Results for the Third Quarter Ended April 30, 2021	14/06/21
NuGenerex Immuno-Oncology, Inc. has completed an IPO in the amount of $50.000004 million.	19/05/21
NUGENEREX IMMUNO-ONCOLOGY, INC. : Other Events (form 8-K)	27/04/21
NuGenerex Immuno-Oncology, Inc. Submits Protocol, Data, and Manufacturing Information to FDA in Advance of the IND Submission	12/04/21
NUGENEREX IMMUNO ONCOLOGY : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	12/03/21
Nugenerex Immuno-Oncology, Inc. Reports Earnings Results for the Second Quarter Ended January 31, 2021	12/03/21
Nugenerex Immuno-Oncology, Inc. and Generex Biotechnology Corporation Signs an Extension for the Receipt of the USD 5,000,000.00 Upfront Licensing Fee Payment	17/12/20
NuGenerex to Seek Merger or Acquisition Opportunities	15/12/20
Generex Biotechnology Corporation and Nugenerex Immuno-Oncology Grants Licensing Rights to Bintai Healthcare Sdn Bhd	25/11/20
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 Vaccine Partner Bintai Kinden Executes its Exclusive Distribution & Licensing Option for Australia and New Zealand	23/11/20
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology, Inc. Sign Distribution and Licensing Agreement with Bintai Healthcare SDN BHD	09/10/20
NuGenerex Immuno-Oncology Announces Closing of a Licensing & Distribution Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Global Markets	07/10/20
Bintai Healthcare Sdn Bhd Enters into A Distribution and Licensing Agreement with Generex Biotechnology Corporation and Its Majority Owned Subsidiary, Nugenerex Immuno-Oncology, Inc	06/10/20
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology, Inc. Sign Agreement with Bintai Kinden Corporation of Malaysia for the Development and Commercialization of the II-Key-SARS-CoV-2 Coronavirus Vaccine	24/09/20
NuGenerex Immuno-Oncology, Inc. has filed an IPO in the amount of $1 million.	14/09/20
Bintai Kinden Corporation Berhad Announces Memorandum of Understanding with Nugenerex Immuno-Oncology on New Business Opportunity (COVID-19 Vaccine)	17/08/20
Nugenerex Immuno-Oncology Closes $50 Million Financing Facility	15/07/20

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues NuGenerex Immuno-Oncology, Inc.

Actions

NUGX

US67053X1028

Autres langues

Filtres